The approval was based on the positive outcomes from the pivotal ROSELLA trial, which involved 381 patients with platinum-resistant ovarian cancer. The trial demonstrated that patients receiving Lifyorli in addition to nab-paclitaxel experienced a 35% reduction in the risk of death compared to those receiving nab-paclitaxel alone, with a median overall survival of 16.0 months versus 11.9 months. Furthermore, the combination therapy also resulted in a 30% reduction in the risk of disease progression, showcasing its efficacy in improving patient outcomes.
The safety profile of Lifyorli was assessed in a pooled analysis from the ROSELLA trial and a Phase 2 trial, indicating that the combination therapy was well-tolerated. Common adverse reactions included decreased hemoglobin, fatigue, and nausea, with monitoring recommended for potential neutropenia and severe infections.
This approval is expected to have a substantial positive impact on Corcept's stock price, as it not only enhances the company's product portfolio but also addresses a significant unmet medical need in the oncology space. The combination of Lifyorli with nab-paclitaxel is anticipated to become a new standard-of-care treatment for patients with platinum-resistant ovarian cancer, providing clinicians with a compelling option to help patients facing this difficult-to-treat disease.
